Paxalisib
Sign in to save this workspacePrimary targets: PI3K, MTOR_FRAP1 · FDA status: FDA Phase III Trials to begin
Selectivity scorecard
KISS
99.75
Gini
0.609
CATDS
0.039
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Paxalisib. Strongest target: CHK1 at 95.2% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CHK1 | 95.2% | 4.8% |
| 2 | MTOR_FRAP1 | 81.2% | 18.8% |
| 3 | RAF1 | 54.2% | 45.8% |
| 4 | MLK2_MAP3K10 | 46.7% | 53.3% |
| 5 | YES_YES1 | 42.8% | 57.2% |
| 6 | MLK3_MAP3K11 | 38.6% | 61.4% |
| 7 | CAMK2D | 35.8% | 64.2% |
| 8 | RSK3 | 34.1% | 65.9% |
| 9 | LCK | 29.5% | 70.5% |
| 10 | BTK | 27.1% | 72.9% |
| 11 | CDK3_CYCLIN_C | 26.6% | 73.4% |
| 12 | HCK | 26.0% | 74.0% |
| 13 | CAMK2A | 24.1% | 75.9% |
| 14 | PAK4 | 22.5% | 77.5% |
| 15 | SYK | 22.3% | 77.7% |
| 16 | FLT3 | 20.6% | 79.4% |
| 17 | BLK | 20.2% | 79.8% |
| 18 | FYN | 20.2% | 79.8% |
| 19 | TXK | 19.4% | 80.6% |
| 20 | FGR | 19.1% | 80.9% |
Selectivity landscape
Where Paxalisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Paxalisib.
Annotations
Sign in to read and post annotations.
Loading…